Northern Light Venture Capital Leads Tens of Millions RMB Series A Round in Nomic Bio to Accelerate NO Therapy Commercialization Amid Hong Kong IPO Filing

VCBeat (WeChat ID: vcbeat) has learned that Nanjing Nollet Biotechnology Co., Ltd. (hereinafter referred to as “Noliving Biotech”) recently announced the completion of its Series A financing round, amounting to tens of millions of yuan.byLed by new investor Northern Light Venture Capital, with follow-on investment from existing investor Nanjing Yingmeng, the proceeds from the financing will be primarily used to advance the clinical trials of the company’s Class III medical device products related to nitric oxide (NO).

Previously, Noliving Biotech completed its angel round of financing in late 2019, with participation from Nanjing Yingmeng.

“From the angel round to Series A, Noliving Biotech has achieved remarkable results in just over a year. We have completed the development of two nitric oxide (NO) generators, with our flagship product poised to obtain the registration testing report and enter the clinical trial phase.”Dr. Mao Wen, CEO of Noliving Biotech“Noliving Biotech stated, ‘Our portable NO generator is the world’s first Class III medical device that utilizes electrochemical chelation catalysis technology to generate nitric oxide (NO) gas in real time. It can be used independently or in conjunction with a variety of ventilators. The device ensures the production of high-purity NO gas through precise control and proportioning of raw materials, enabling a unique micro-release controlled reaction system. Noliving’s technological innovations optimize the cost-effectiveness of NO therapy, aligning with the future healthcare pricing structure in China.’”

It is reported that the cost of nitric oxide (NO) gas therapy abroad is extremely high, with daily treatment expenses for a single patient reaching as much as $3,000.

In 2020, nitric oxide (NO) gas therapy emerged as a rapidly rising product and treatment regimen amid the pandemic.In March 2020 alone, the U.S. FDA granted emergency use authorization to two inhaled nitric oxide (NO) therapy products from different companies for the treatment of COVID-19.. Currently, the United States isEight new indications are undergoing FDA registration and approval.. The nitric oxide-related therapeutic sector is poised to enter its golden age. Currently, NO gas therapy technologies are concentrated in the United States, making it a blue-ocean market in China. Noliving Biotech is currently the only company with an original NO gas-generating therapeutic product.

Noliving Biotech’s medical-grade nitric oxide (NO) technology has disrupted traditional industrial production and subsequent medical translation processes, representing a breakthrough achievement in the field of medical NO applications over the past few decades. Its unique portable electrochemical generation technology enables on-demand production and immediate use of NO gas.Ventilator Combination Technology Covering Neonates to Adults, enabling real-time monitoring of the patient's breathing pattern to ensure the stability and safety of NO delivery.

Recently, Noliving Biotech has further upgraded its NO sensor technology to ensure greater accuracy and safety in NO therapy. The company’s latest product development portfolio now covers indications such as asthma, diabetic foot, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD), marking Noliving Biotech’s transition toward comprehensive applications in the medical use of nitric oxide.

Regarding the investment in Noliving Biotech,Lead Investor: Northern Light Venture CapitalIt stated: “Nitric oxide is the first endogenous gas molecule discovered to be involved in cell signaling, and the related research by three scientists was awarded the Nobel Prize. The use of NO for various indications has been applied clinically in the United States for many years, included in relevant guidelines, with multiple additional indications currently under clinical investigation. Meanwhile, innovative research surrounding the generation and release of NO gas continues to advance.”

“Noliving Biotech is a rare team that boasts years of comprehensive technical expertise, deep insights into the healthcare market, and exceptional execution capabilities. Meanwhile, the domestic market holds vast untapped potential, presenting an exciting opportunity in both existing and incremental segments. We are confident that Noliving Biotech will deliver substantial returns to investors while creating significant clinical value.”

Existing Shareholder: Nanjing YingmengIt was also acknowledged that: “The scientists at Noliving Biotech hail from the University of Michigan in the United States, possessing unique technological advantages in nitric oxide (NO)-related fields and ranking among the global leaders. Meanwhile, the founding team comprises multidisciplinary professionals with extensive industry experience; their exceptional management capabilities and market innovation skills ensure the rapid development of this blue-ocean sector. Furthermore, Noliving can leverage technology to build a platform-based business model centered on the ‘NO Factory’ concept. We are confident that Noliving will emerge as a leading company in the global industrialization of NO, with promising prospects ahead.”

Noliving Biotech specializes in the generation and sustained release of nitric oxide (NO) and its medical applications, striving to lead the global advancement of NO therapies for pulmonary hypertension and infectious diseases. As the first medical device company in China dedicated to NO gas generation, Noliving Biotech has developed NO gas generators for treating rare or complex conditions such as pulmonary hypertension, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), and diabetic foot, leveraging the diverse therapeutic values of NO in clinical settings. Furthermore, the company’s innovative technologies for the preparation and production of NO-releasing polymer materials have enabled the antimicrobial properties of NO to drive industrial growth across multiple sectors in healthcare and general wellness, fostering a safer and healthier lifestyle and enhancing human well-being.

Northern Light Venture Capital was founded by Mr. Deng Feng in 2005, with the mission of “empowering world-class Chinese entrepreneurs and cultivating world-class Chinese enterprises.” It has long focused on investing in early-stage, technology-driven innovative companies. To date, it has invested in nearly 400 outstanding enterprises in the TMT, advanced technology, and healthcare sectors. Northern Light Venture Capital entered the healthcare sector in 2009. Over the past decade, its investments have spanned multiple sub-sectors, including medical devices, in vitro diagnostics, biopharmaceuticals, healthcare services, and E-Health, covering virtually the entire industry chain. The firm has invested in more than 60 companies, including CITIC Pharmaceutical, BGI Genomics, Burning Rock Biotech, Zeltis Pharma, iRay Technology, Taimei Medical Technology, Cytek Biosciences, Guoke Hengtai, Conatus Pharmaceuticals, Convoy Therapeutics, Yidao Biologics, East West Speech Therapy, and CoYDx.

Eagle Alliance Capital is a firm specializing in equity investment and fund management. It currently manages four private equity funds, with primary investment focus on strategic emerging industries such as biopharmaceuticals, semiconductors, integrated circuits, next-generation information technology, intelligent manufacturing, and military equipment.

Eagle Alliance Capital continuously seeks strategic investment opportunities by focusing on the global technological frontier and the “chokepoint” technologies that constrain China’s development. Leveraging the substantial strength of its manager and sponsors, as well as extensive resources across platforms such as listed companies, investment banks, research and consulting firms, and asset management entities, Eagle Alliance Capital integrates capital with industrial resources to propel advanced enterprises toward rapid growth.